Anticoagulation and antiplatelet strategies used in Sweden in patients with myocardial infarction and concomitant atrial fibrillation: nationwide cohort study
Open Access
- 1 July 2025
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 12 (2) , e003472
Abstract
Background: Optimal antithrombotic therapy and its duration, whether triple therapy with dual antiplatelets plus oral anticoagulant (OAC), or dual antithrombotic therapy with an antiplatelet plus OAC, is uncertain for patients with myocardial infarction (MI) and atrial fibrillation (AF). Methods: Patients registered in SWEDEHEART (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) for their first MI between 2011 and 2021 with a history or new-onset AF were included (n=26 574). Linkage between SWEDEHEART and Swedish administrative health databases was performed, and pseudonymised data analysed. Results: Over time, OAC use at discharge after MI tripled from 27% in 2011 to 77% in 2021, with direct OACs (DOACs) largely replacing warfarin, predominantly in combination with a single antiplatelet. The strongest factors for initiating OAC therapy were the performance of coronary angiography (OR 1.53 (1.40–1.68)), and percutaneous coronary intervention (OR 1.49 (1.39–1.61)). However, the year of the MI was the most predictive variable associated with OAC initiation, with an OR of 9.31 (7.92–10.95) in 2021 compared with 2011. The clinical factors associated with lower likelihood of OAC initiation were dementia, liver disease, cancer and ST-elevation MI (STEMI) versus non-STEMI. Conclusions: Use of OAC has increased over the years in patients with MI and concurrent AF, primarily driven by the increased adoption of DOACs. Additionally, there has been a shift in antithrombotic combinations, with most patients in recent years receiving DOAC in combination with a single antiplatelet, reflecting the nationwide implementation of recent evidence and guidelines. However, significant variation in antithrombotic therapy strategies remains.Keywords
Funding Information
- Bristol Myers Squibb
- Pfizer
This publication has 30 references indexed in Scilit:
- Outcomes in patients with acute myocardial infarction and new atrial fibrillation: a nationwide analysisClinical Research in Cardiology, 2021
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trialThe Lancet, 2019
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationNew England Journal of Medicine, 2019
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationNew England Journal of Medicine, 2017
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCINew England Journal of Medicine, 2016
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary SyndromesJAMA, 2006
- Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarctionThe Lancet, 1993